Sartorius Stedim Biotech’s shares advanced 5% on Tuesday, reaching €192.1 after opening at €187 and briefly touching a session high of €195.1. The move followed an upgrade from UBS, which raised its recommendation on the stock to Buy from Neutral and lifted its price target to €260, up from €220.
The Swiss bank also raised its average revenue and earnings forecasts through 2031 by approximately 3%, citing structurally strong demand for bioprocess consumables. UBS highlighted the increasing share of biologic assets in biopharma research and development pipelines, as well as the expected wave of blockbuster biosimilar launches between 2028 and 2030.
The stock’s surge contrasted with broader market trends. The CAC 40 in Paris edged lower in the prior session, pressured by weakness in financials and industrials, while U.S. equity benchmarks remained essentially flat. Analysts attributed the sharp move in Sartorius Stedim Biotech shares to company-specific developments rather than broader sector or macroeconomic factors.
